Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-11-18

AUTHORS

Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller, Naureen Starling, David Cunningham, Michal Bassani-Sternberg, Marco Gerlinger

ABSTRACT

BackgroundPatient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics to investigate neoantigen presentation and whether this can be augmented through interferon gamma (IFNγ) or MEK-inhibitor treatment.MethodsFour microsatellite stable PDOs from chemotherapy refractory and one from a treatment naïve CRC were expanded to replicates with 100 million cells each, and HLA class I and class II peptide ligands were analyzed by MS.ResultsWe identified an average of 9936 unique peptides per PDO which compares favorably against published immunopeptidomics studies, suggesting high sensitivity. Loss of heterozygosity of the HLA locus was associated with low peptide diversity in one PDO. Peptides from genes without detectable expression by RNA-sequencing were rarely identified by MS. Only 3 out of 612 non-silent mutations encoded for neoantigens that were detected by MS. In contrast, computational HLA binding prediction estimated that 304 mutations could generate neoantigens. One hundred ninety-six of these were located in expressed genes, still exceeding the number of MS-detected neoantigens 65-fold. Treatment of four PDOs with IFNγ upregulated HLA class I expression and qualitatively changed the immunopeptidome, with increased presentation of IFNγ-inducible genes. HLA class II presented peptides increased dramatically with IFNγ treatment. MEK-inhibitor treatment showed no consistent effect on HLA class I or II expression or the peptidome. Importantly, no additional HLA class I or II presented neoantigens became detectable with any treatment.ConclusionsOnly 3 out of 612 non-silent mutations encoded for neoantigens that were detectable by MS. Although MS has sensitivity limits and biases, and likely underestimated the true neoantigen burden, this established a lower bound of the percentage of non-silent mutations that encode for presented neoantigens, which may be as low as 0.5%. This could be a reason for the poor responses of non-hypermutated CRCs to immune checkpoint inhibitors. MEK-inhibitors recently failed to improve checkpoint-inhibitor efficacy in CRC and the observed lack of HLA upregulation or improved peptide presentation may explain this. More... »

PAGES

309

References to SciGraph publications

  • 2017-07-05. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer in NATURE
  • 2017-11-03. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis in NATURE COMMUNICATIONS
  • 2016-06-27. The Perseus computational platform for comprehensive analysis of (prote)omics data in NATURE METHODS
  • 2016-11-21. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry in NATURE COMMUNICATIONS
  • 2015-09-15. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes in NATURE BIOTECHNOLOGY
  • 2016-01-05. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames in NATURE COMMUNICATIONS
  • 2019-04-30. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma in GENOME MEDICINE
  • 2017-07-05. An immunogenic personal neoantigen vaccine for patients with melanoma in NATURE
  • 2012-07-18. Comprehensive molecular characterization of human colon and rectal cancer in NATURE
  • 2019-04-15. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-10-14. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes in NATURE BIOTECHNOLOGY
  • 2007-09-15. Clinical impact of HLA class I expression in rectal cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s40425-019-0769-8

    DOI

    http://dx.doi.org/10.1186/s40425-019-0769-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1122665757

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/31735170


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antigens, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Colorectal Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Histocompatibility Antigens Class I", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Interferon-gamma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "MAP Kinase Kinase Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organoids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peptides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proteomics", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Newey", 
            "givenName": "Alice", 
            "id": "sg:person.013537212473.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013537212473.30"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Griffiths", 
            "givenName": "Beatrice", 
            "id": "sg:person.010411247077.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010411247077.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Michaux", 
            "givenName": "Justine", 
            "id": "sg:person.012751043412.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012751043412.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pak", 
            "givenName": "Hui Song", 
            "id": "sg:person.01151605300.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151605300.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Vital IT, Swiss Institute of Bioinformatics, 1015, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419765.8", 
              "name": [
                "Vital IT, Swiss Institute of Bioinformatics, 1015, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stevenson", 
            "givenName": "Brian J.", 
            "id": "sg:person.01006545240.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006545240.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Woolston", 
            "givenName": "Andrew", 
            "id": "sg:person.01145246415.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145246415.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Semiannikova", 
            "givenName": "Maria", 
            "id": "sg:person.016021564617.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016021564617.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Spain", 
            "givenName": "Georgia", 
            "id": "sg:person.010147412422.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010147412422.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Barber", 
            "givenName": "Louise J.", 
            "id": "sg:person.01231216510.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231216510.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Tumour Profiling Unit, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Tumour Profiling Unit, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Matthews", 
            "givenName": "Nik", 
            "id": "sg:person.01006330237.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006330237.21"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rao", 
            "givenName": "Sheela", 
            "id": "sg:person.01321127272.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321127272.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Watkins", 
            "givenName": "David", 
            "id": "sg:person.0723551231.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723551231.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chau", 
            "givenName": "Ian", 
            "id": "sg:person.01035560774.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Coukos", 
            "givenName": "George", 
            "id": "sg:person.0755753535.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755753535.69"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419765.8", 
              "name": [
                "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland", 
                "Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Racle", 
            "givenName": "Julien", 
            "id": "sg:person.0645276403.10", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645276403.10"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.419765.8", 
              "name": [
                "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland", 
                "Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gfeller", 
            "givenName": "David", 
            "id": "sg:person.0714173665.31", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714173665.31"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Starling", 
            "givenName": "Naureen", 
            "id": "sg:person.01136565472.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cunningham", 
            "givenName": "David", 
            "id": "sg:person.01320161130.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bassani-Sternberg", 
            "givenName": "Michal", 
            "id": "sg:person.0750021441.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750021441.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.424926.f", 
              "name": [
                "Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK", 
                "GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gerlinger", 
            "givenName": "Marco", 
            "id": "sg:person.0615030103.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615030103.67"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/s41467-017-01358-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092446353", 
              "https://doi.org/10.1038/s41467-017-01358-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-007-0396-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007239063", 
              "https://doi.org/10.1007/s00262-007-0396-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature22991", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090346424", 
              "https://doi.org/10.1038/nature22991"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41587-019-0289-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1121784502", 
              "https://doi.org/10.1038/s41587-019-0289-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nmeth.3901", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032398342", 
              "https://doi.org/10.1038/nmeth.3901"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature11252", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010619765", 
              "https://doi.org/10.1038/nature11252"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms13404", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047763471", 
              "https://doi.org/10.1038/ncomms13404"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt.3344", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005491724", 
              "https://doi.org/10.1038/nbt.3344"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13073-019-0636-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113843631", 
              "https://doi.org/10.1186/s13073-019-0636-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-019-0575-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113479463", 
              "https://doi.org/10.1186/s40425-019-0575-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature23003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090351728", 
              "https://doi.org/10.1038/nature23003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms10238", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035838720", 
              "https://doi.org/10.1038/ncomms10238"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-11-18", 
        "datePublishedReg": "2019-11-18", 
        "description": "BackgroundPatient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics to investigate neoantigen presentation and whether this can be augmented through interferon gamma (IFN\u03b3) or MEK-inhibitor treatment.MethodsFour microsatellite stable PDOs from chemotherapy refractory and one from a treatment na\u00efve CRC were expanded to replicates with 100 million cells each, and HLA class I and class II peptide ligands were analyzed by MS.ResultsWe identified an average of 9936 unique peptides per PDO which compares favorably against published immunopeptidomics studies, suggesting high sensitivity. Loss of heterozygosity of the HLA locus was associated with low peptide diversity in one PDO. Peptides from genes without detectable expression by RNA-sequencing were rarely identified by MS. Only 3 out of 612 non-silent mutations encoded for neoantigens that were detected by MS. In contrast, computational HLA binding prediction estimated that 304 mutations could generate neoantigens. One hundred ninety-six of these were located in expressed genes, still exceeding the number of MS-detected neoantigens 65-fold. Treatment of four PDOs with IFN\u03b3 upregulated HLA class I expression and qualitatively changed the immunopeptidome, with increased presentation of IFN\u03b3-inducible genes. HLA class II presented peptides increased dramatically with IFN\u03b3 treatment. MEK-inhibitor treatment showed no consistent effect on HLA class I or II expression or the peptidome. Importantly, no additional HLA class I or II presented neoantigens became detectable with any treatment.ConclusionsOnly 3 out of 612 non-silent mutations encoded for neoantigens that were detectable by MS. Although MS has sensitivity limits and biases, and likely underestimated the true neoantigen burden, this established a lower bound of the percentage of non-silent mutations that encode for presented neoantigens, which may be as low as 0.5%. This could be a reason for the poor responses of non-hypermutated CRCs to immune checkpoint inhibitors. MEK-inhibitors recently failed to improve checkpoint-inhibitor efficacy in CRC and the observed lack of HLA upregulation or improved peptide presentation may explain this.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s40425-019-0769-8", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.7926992", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.4579368", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.5134662", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1049249", 
            "issn": [
              "2051-1426"
            ], 
            "name": "Journal for ImmunoTherapy of Cancer", 
            "publisher": "BMJ", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "7"
          }
        ], 
        "keywords": [
          "HLA class I", 
          "MEK inhibitor treatment", 
          "colorectal cancer", 
          "class I", 
          "non-silent mutations", 
          "additional HLA class I", 
          "immune checkpoint inhibitors", 
          "checkpoint inhibitor efficacy", 
          "HLA class II", 
          "colorectal cancer organoids", 
          "chemotherapy refractory", 
          "HLA upregulation", 
          "checkpoint inhibitors", 
          "neoantigen burden", 
          "poor response", 
          "neoantigen presentation", 
          "loss of heterozygosity", 
          "clinical relevance", 
          "neoantigens", 
          "IFN\u03b3-inducible genes", 
          "IFN\u03b3 treatment", 
          "neoantigen landscape", 
          "peptide presentation", 
          "class II", 
          "cancer organoids", 
          "MEK inhibitors", 
          "HLA loci", 
          "immunopeptidomics studies", 
          "treatment", 
          "detectable expression", 
          "cancer biology", 
          "presentation", 
          "RNA sequencing", 
          "consistent effect", 
          "immunopeptidomics", 
          "organoids", 
          "mutations", 
          "peptides", 
          "peptide ligands", 
          "BackgroundPatients", 
          "IFN\u03b3", 
          "HLA", 
          "expression", 
          "interferon", 
          "cancer", 
          "ResultsWe", 
          "genes", 
          "upregulation", 
          "efficacy", 
          "immunopeptidome", 
          "burden", 
          "refractory", 
          "inhibitors", 
          "unique peptides", 
          "MS", 
          "cells", 
          "observed lack", 
          "high sensitivity", 
          "percentage", 
          "peptidome", 
          "response", 
          "gamma", 
          "study", 
          "sensitivity", 
          "increase", 
          "contrast", 
          "lack", 
          "relevance", 
          "loss", 
          "peptide diversity", 
          "effect", 
          "average", 
          "heterozygosity", 
          "sensitivity limit", 
          "biology", 
          "number", 
          "reasons", 
          "ligands", 
          "loci", 
          "model", 
          "biases", 
          "prediction", 
          "limit", 
          "diversity", 
          "landscape", 
          "PDO"
        ], 
        "name": "Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment", 
        "pagination": "309", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1122665757"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s40425-019-0769-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "31735170"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s40425-019-0769-8", 
          "https://app.dimensions.ai/details/publication/pub.1122665757"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:46", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_810.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s40425-019-0769-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0769-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0769-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0769-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0769-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    400 TRIPLES      21 PREDICATES      136 URIs      116 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s40425-019-0769-8 schema:about N212499bf1e87450e891f53850de9af96
    2 N30c31d48221d435d9f90d0159e875546
    3 N3d2daa58bde14a0fb27a2719a018e75f
    4 N4c12b83f52c34ca0b5d9b2ab427daad1
    5 N60c5275579a441cdbeffa3c44785282d
    6 N748b0b5ccb3d42708e0f6fd1fa434c24
    7 N79bde2f7b24f4a6da02c0ea5686d9ca0
    8 N9a37af03d2f349589e0f16981e5cb051
    9 Na44494a6c6754c59b3d774f631c58cf9
    10 Nb21fdde9b180415cba3bcda84ecf2179
    11 Ndeb3bdaad5054630bb88db6ae81ddda1
    12 Nec1cd36912954ce898051c3702c5884b
    13 Nf4ed88c888ff4203bdfe8b521ca7c25b
    14 anzsrc-for:11
    15 anzsrc-for:1112
    16 schema:author Nee29c61ab1cc4e729284433c0357ca92
    17 schema:citation sg:pub.10.1007/s00262-007-0396-y
    18 sg:pub.10.1038/nature11252
    19 sg:pub.10.1038/nature22991
    20 sg:pub.10.1038/nature23003
    21 sg:pub.10.1038/nbt.3344
    22 sg:pub.10.1038/ncomms10238
    23 sg:pub.10.1038/ncomms13404
    24 sg:pub.10.1038/nmeth.3901
    25 sg:pub.10.1038/s41467-017-01358-x
    26 sg:pub.10.1038/s41587-019-0289-6
    27 sg:pub.10.1186/s13073-019-0636-8
    28 sg:pub.10.1186/s40425-019-0575-3
    29 schema:datePublished 2019-11-18
    30 schema:datePublishedReg 2019-11-18
    31 schema:description BackgroundPatient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics to investigate neoantigen presentation and whether this can be augmented through interferon gamma (IFNγ) or MEK-inhibitor treatment.MethodsFour microsatellite stable PDOs from chemotherapy refractory and one from a treatment naïve CRC were expanded to replicates with 100 million cells each, and HLA class I and class II peptide ligands were analyzed by MS.ResultsWe identified an average of 9936 unique peptides per PDO which compares favorably against published immunopeptidomics studies, suggesting high sensitivity. Loss of heterozygosity of the HLA locus was associated with low peptide diversity in one PDO. Peptides from genes without detectable expression by RNA-sequencing were rarely identified by MS. Only 3 out of 612 non-silent mutations encoded for neoantigens that were detected by MS. In contrast, computational HLA binding prediction estimated that 304 mutations could generate neoantigens. One hundred ninety-six of these were located in expressed genes, still exceeding the number of MS-detected neoantigens 65-fold. Treatment of four PDOs with IFNγ upregulated HLA class I expression and qualitatively changed the immunopeptidome, with increased presentation of IFNγ-inducible genes. HLA class II presented peptides increased dramatically with IFNγ treatment. MEK-inhibitor treatment showed no consistent effect on HLA class I or II expression or the peptidome. Importantly, no additional HLA class I or II presented neoantigens became detectable with any treatment.ConclusionsOnly 3 out of 612 non-silent mutations encoded for neoantigens that were detectable by MS. Although MS has sensitivity limits and biases, and likely underestimated the true neoantigen burden, this established a lower bound of the percentage of non-silent mutations that encode for presented neoantigens, which may be as low as 0.5%. This could be a reason for the poor responses of non-hypermutated CRCs to immune checkpoint inhibitors. MEK-inhibitors recently failed to improve checkpoint-inhibitor efficacy in CRC and the observed lack of HLA upregulation or improved peptide presentation may explain this.
    32 schema:genre article
    33 schema:isAccessibleForFree true
    34 schema:isPartOf N5faca40a50994d2c9490f3e0af5b7f4f
    35 Na94ee542281f4067bf22f5a689ea707f
    36 sg:journal.1049249
    37 schema:keywords BackgroundPatients
    38 HLA
    39 HLA class I
    40 HLA class II
    41 HLA loci
    42 HLA upregulation
    43 IFNγ
    44 IFNγ treatment
    45 IFNγ-inducible genes
    46 MEK inhibitor treatment
    47 MEK inhibitors
    48 MS
    49 PDO
    50 RNA sequencing
    51 ResultsWe
    52 additional HLA class I
    53 average
    54 biases
    55 biology
    56 burden
    57 cancer
    58 cancer biology
    59 cancer organoids
    60 cells
    61 checkpoint inhibitor efficacy
    62 checkpoint inhibitors
    63 chemotherapy refractory
    64 class I
    65 class II
    66 clinical relevance
    67 colorectal cancer
    68 colorectal cancer organoids
    69 consistent effect
    70 contrast
    71 detectable expression
    72 diversity
    73 effect
    74 efficacy
    75 expression
    76 gamma
    77 genes
    78 heterozygosity
    79 high sensitivity
    80 immune checkpoint inhibitors
    81 immunopeptidome
    82 immunopeptidomics
    83 immunopeptidomics studies
    84 increase
    85 inhibitors
    86 interferon
    87 lack
    88 landscape
    89 ligands
    90 limit
    91 loci
    92 loss
    93 loss of heterozygosity
    94 model
    95 mutations
    96 neoantigen burden
    97 neoantigen landscape
    98 neoantigen presentation
    99 neoantigens
    100 non-silent mutations
    101 number
    102 observed lack
    103 organoids
    104 peptide diversity
    105 peptide ligands
    106 peptide presentation
    107 peptides
    108 peptidome
    109 percentage
    110 poor response
    111 prediction
    112 presentation
    113 reasons
    114 refractory
    115 relevance
    116 response
    117 sensitivity
    118 sensitivity limit
    119 study
    120 treatment
    121 unique peptides
    122 upregulation
    123 schema:name Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
    124 schema:pagination 309
    125 schema:productId N3584d0f0bbb743919fb1c717a9417f1d
    126 N5f0e014e994542dfa15d97dd6854a6f7
    127 N789c0928e970413283eb72920076ac1d
    128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122665757
    129 https://doi.org/10.1186/s40425-019-0769-8
    130 schema:sdDatePublished 2022-10-01T06:46
    131 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    132 schema:sdPublisher N9a38d592fb784512bc8e9e9fde082b39
    133 schema:url https://doi.org/10.1186/s40425-019-0769-8
    134 sgo:license sg:explorer/license/
    135 sgo:sdDataset articles
    136 rdf:type schema:ScholarlyArticle
    137 N212499bf1e87450e891f53850de9af96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Organoids
    139 rdf:type schema:DefinedTerm
    140 N27549d940ef84bf9a259899c9740ab4d rdf:first sg:person.01006330237.21
    141 rdf:rest Ne39577b6e29343f3a1ebfea868fa49ee
    142 N2c9671f1d6864af587139c51b3191805 rdf:first sg:person.01136565472.17
    143 rdf:rest N94fe28bcf789457fa1f80a699a87f473
    144 N30c31d48221d435d9f90d0159e875546 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Antigens, Neoplasm
    146 rdf:type schema:DefinedTerm
    147 N3584d0f0bbb743919fb1c717a9417f1d schema:name dimensions_id
    148 schema:value pub.1122665757
    149 rdf:type schema:PropertyValue
    150 N3d2daa58bde14a0fb27a2719a018e75f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Histocompatibility Antigens Class I
    152 rdf:type schema:DefinedTerm
    153 N3f7c93e174f146039d4c14fa89fda91e rdf:first sg:person.0714173665.31
    154 rdf:rest N2c9671f1d6864af587139c51b3191805
    155 N44dfe2eebc32476d98582bdffdda38ba rdf:first sg:person.01231216510.66
    156 rdf:rest N27549d940ef84bf9a259899c9740ab4d
    157 N4c12b83f52c34ca0b5d9b2ab427daad1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Humans
    159 rdf:type schema:DefinedTerm
    160 N4ff1999c5f5f484e9c20bc1921cead8a rdf:first sg:person.0750021441.44
    161 rdf:rest N6368c50690ec480196c7bbdb6d3a716c
    162 N5f0e014e994542dfa15d97dd6854a6f7 schema:name doi
    163 schema:value 10.1186/s40425-019-0769-8
    164 rdf:type schema:PropertyValue
    165 N5faca40a50994d2c9490f3e0af5b7f4f schema:volumeNumber 7
    166 rdf:type schema:PublicationVolume
    167 N60c5275579a441cdbeffa3c44785282d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Protein Kinase Inhibitors
    169 rdf:type schema:DefinedTerm
    170 N6368c50690ec480196c7bbdb6d3a716c rdf:first sg:person.0615030103.67
    171 rdf:rest rdf:nil
    172 N748b0b5ccb3d42708e0f6fd1fa434c24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Male
    174 rdf:type schema:DefinedTerm
    175 N789c0928e970413283eb72920076ac1d schema:name pubmed_id
    176 schema:value 31735170
    177 rdf:type schema:PropertyValue
    178 N79bde2f7b24f4a6da02c0ea5686d9ca0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name MAP Kinase Kinase Kinases
    180 rdf:type schema:DefinedTerm
    181 N7f6c47105dca40a0884b3fd582bd306f rdf:first sg:person.01145246415.46
    182 rdf:rest N9eab0187ede3436f885b1bfb7f1e7203
    183 N827e5c0b2c614c5bb7cb1495496e9ab3 rdf:first sg:person.01151605300.49
    184 rdf:rest N847e2f59da5640a4bfb843a7114750f8
    185 N847e2f59da5640a4bfb843a7114750f8 rdf:first sg:person.01006545240.44
    186 rdf:rest N7f6c47105dca40a0884b3fd582bd306f
    187 N8785ba5fab594b989576e926efd82d57 rdf:first sg:person.0645276403.10
    188 rdf:rest N3f7c93e174f146039d4c14fa89fda91e
    189 N90faf111b9c5481794bbe34e1cd1ef7f rdf:first sg:person.0755753535.69
    190 rdf:rest N8785ba5fab594b989576e926efd82d57
    191 N94fe28bcf789457fa1f80a699a87f473 rdf:first sg:person.01320161130.16
    192 rdf:rest N4ff1999c5f5f484e9c20bc1921cead8a
    193 N9a37af03d2f349589e0f16981e5cb051 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Peptides
    195 rdf:type schema:DefinedTerm
    196 N9a38d592fb784512bc8e9e9fde082b39 schema:name Springer Nature - SN SciGraph project
    197 rdf:type schema:Organization
    198 N9eab0187ede3436f885b1bfb7f1e7203 rdf:first sg:person.016021564617.54
    199 rdf:rest Nd37f342c56244beca8451c7d54f9de2c
    200 Na44494a6c6754c59b3d774f631c58cf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    201 schema:name Colorectal Neoplasms
    202 rdf:type schema:DefinedTerm
    203 Na729835246d04712a4fadc53208fdc8a rdf:first sg:person.0723551231.39
    204 rdf:rest Nce0ed29915fc4d3abb93db45d9a312c2
    205 Na885472a54d341958b4f5592ded647ff rdf:first sg:person.012751043412.07
    206 rdf:rest N827e5c0b2c614c5bb7cb1495496e9ab3
    207 Na94ee542281f4067bf22f5a689ea707f schema:issueNumber 1
    208 rdf:type schema:PublicationIssue
    209 Nb21fdde9b180415cba3bcda84ecf2179 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Proteomics
    211 rdf:type schema:DefinedTerm
    212 Nc86b71384a9042839d6b93b2d1fee18a rdf:first sg:person.010411247077.27
    213 rdf:rest Na885472a54d341958b4f5592ded647ff
    214 Nce0ed29915fc4d3abb93db45d9a312c2 rdf:first sg:person.01035560774.45
    215 rdf:rest N90faf111b9c5481794bbe34e1cd1ef7f
    216 Nd37f342c56244beca8451c7d54f9de2c rdf:first sg:person.010147412422.77
    217 rdf:rest N44dfe2eebc32476d98582bdffdda38ba
    218 Ndeb3bdaad5054630bb88db6ae81ddda1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    219 schema:name Interferon-gamma
    220 rdf:type schema:DefinedTerm
    221 Ne39577b6e29343f3a1ebfea868fa49ee rdf:first sg:person.01321127272.55
    222 rdf:rest Na729835246d04712a4fadc53208fdc8a
    223 Nec1cd36912954ce898051c3702c5884b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    224 schema:name Middle Aged
    225 rdf:type schema:DefinedTerm
    226 Nee29c61ab1cc4e729284433c0357ca92 rdf:first sg:person.013537212473.30
    227 rdf:rest Nc86b71384a9042839d6b93b2d1fee18a
    228 Nf4ed88c888ff4203bdfe8b521ca7c25b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    229 schema:name Female
    230 rdf:type schema:DefinedTerm
    231 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    232 schema:name Medical and Health Sciences
    233 rdf:type schema:DefinedTerm
    234 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    235 schema:name Oncology and Carcinogenesis
    236 rdf:type schema:DefinedTerm
    237 sg:grant.4579368 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-019-0769-8
    238 rdf:type schema:MonetaryGrant
    239 sg:grant.5134662 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-019-0769-8
    240 rdf:type schema:MonetaryGrant
    241 sg:grant.7926992 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-019-0769-8
    242 rdf:type schema:MonetaryGrant
    243 sg:journal.1049249 schema:issn 2051-1426
    244 schema:name Journal for ImmunoTherapy of Cancer
    245 schema:publisher BMJ
    246 rdf:type schema:Periodical
    247 sg:person.01006330237.21 schema:affiliation grid-institutes:grid.18886.3f
    248 schema:familyName Matthews
    249 schema:givenName Nik
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006330237.21
    251 rdf:type schema:Person
    252 sg:person.01006545240.44 schema:affiliation grid-institutes:grid.419765.8
    253 schema:familyName Stevenson
    254 schema:givenName Brian J.
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006545240.44
    256 rdf:type schema:Person
    257 sg:person.010147412422.77 schema:affiliation grid-institutes:grid.18886.3f
    258 schema:familyName Spain
    259 schema:givenName Georgia
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010147412422.77
    261 rdf:type schema:Person
    262 sg:person.01035560774.45 schema:affiliation grid-institutes:grid.424926.f
    263 schema:familyName Chau
    264 schema:givenName Ian
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035560774.45
    266 rdf:type schema:Person
    267 sg:person.010411247077.27 schema:affiliation grid-institutes:grid.18886.3f
    268 schema:familyName Griffiths
    269 schema:givenName Beatrice
    270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010411247077.27
    271 rdf:type schema:Person
    272 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.424926.f
    273 schema:familyName Starling
    274 schema:givenName Naureen
    275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
    276 rdf:type schema:Person
    277 sg:person.01145246415.46 schema:affiliation grid-institutes:grid.18886.3f
    278 schema:familyName Woolston
    279 schema:givenName Andrew
    280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145246415.46
    281 rdf:type schema:Person
    282 sg:person.01151605300.49 schema:affiliation grid-institutes:grid.9851.5
    283 schema:familyName Pak
    284 schema:givenName Hui Song
    285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151605300.49
    286 rdf:type schema:Person
    287 sg:person.01231216510.66 schema:affiliation grid-institutes:grid.18886.3f
    288 schema:familyName Barber
    289 schema:givenName Louise J.
    290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231216510.66
    291 rdf:type schema:Person
    292 sg:person.012751043412.07 schema:affiliation grid-institutes:grid.9851.5
    293 schema:familyName Michaux
    294 schema:givenName Justine
    295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012751043412.07
    296 rdf:type schema:Person
    297 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.424926.f
    298 schema:familyName Cunningham
    299 schema:givenName David
    300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
    301 rdf:type schema:Person
    302 sg:person.01321127272.55 schema:affiliation grid-institutes:grid.424926.f
    303 schema:familyName Rao
    304 schema:givenName Sheela
    305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321127272.55
    306 rdf:type schema:Person
    307 sg:person.013537212473.30 schema:affiliation grid-institutes:grid.18886.3f
    308 schema:familyName Newey
    309 schema:givenName Alice
    310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013537212473.30
    311 rdf:type schema:Person
    312 sg:person.016021564617.54 schema:affiliation grid-institutes:grid.18886.3f
    313 schema:familyName Semiannikova
    314 schema:givenName Maria
    315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016021564617.54
    316 rdf:type schema:Person
    317 sg:person.0615030103.67 schema:affiliation grid-institutes:grid.424926.f
    318 schema:familyName Gerlinger
    319 schema:givenName Marco
    320 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615030103.67
    321 rdf:type schema:Person
    322 sg:person.0645276403.10 schema:affiliation grid-institutes:grid.419765.8
    323 schema:familyName Racle
    324 schema:givenName Julien
    325 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645276403.10
    326 rdf:type schema:Person
    327 sg:person.0714173665.31 schema:affiliation grid-institutes:grid.419765.8
    328 schema:familyName Gfeller
    329 schema:givenName David
    330 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714173665.31
    331 rdf:type schema:Person
    332 sg:person.0723551231.39 schema:affiliation grid-institutes:grid.424926.f
    333 schema:familyName Watkins
    334 schema:givenName David
    335 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723551231.39
    336 rdf:type schema:Person
    337 sg:person.0750021441.44 schema:affiliation grid-institutes:grid.9851.5
    338 schema:familyName Bassani-Sternberg
    339 schema:givenName Michal
    340 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750021441.44
    341 rdf:type schema:Person
    342 sg:person.0755753535.69 schema:affiliation grid-institutes:grid.9851.5
    343 schema:familyName Coukos
    344 schema:givenName George
    345 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755753535.69
    346 rdf:type schema:Person
    347 sg:pub.10.1007/s00262-007-0396-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1007239063
    348 https://doi.org/10.1007/s00262-007-0396-y
    349 rdf:type schema:CreativeWork
    350 sg:pub.10.1038/nature11252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010619765
    351 https://doi.org/10.1038/nature11252
    352 rdf:type schema:CreativeWork
    353 sg:pub.10.1038/nature22991 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090346424
    354 https://doi.org/10.1038/nature22991
    355 rdf:type schema:CreativeWork
    356 sg:pub.10.1038/nature23003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090351728
    357 https://doi.org/10.1038/nature23003
    358 rdf:type schema:CreativeWork
    359 sg:pub.10.1038/nbt.3344 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005491724
    360 https://doi.org/10.1038/nbt.3344
    361 rdf:type schema:CreativeWork
    362 sg:pub.10.1038/ncomms10238 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035838720
    363 https://doi.org/10.1038/ncomms10238
    364 rdf:type schema:CreativeWork
    365 sg:pub.10.1038/ncomms13404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047763471
    366 https://doi.org/10.1038/ncomms13404
    367 rdf:type schema:CreativeWork
    368 sg:pub.10.1038/nmeth.3901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032398342
    369 https://doi.org/10.1038/nmeth.3901
    370 rdf:type schema:CreativeWork
    371 sg:pub.10.1038/s41467-017-01358-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1092446353
    372 https://doi.org/10.1038/s41467-017-01358-x
    373 rdf:type schema:CreativeWork
    374 sg:pub.10.1038/s41587-019-0289-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121784502
    375 https://doi.org/10.1038/s41587-019-0289-6
    376 rdf:type schema:CreativeWork
    377 sg:pub.10.1186/s13073-019-0636-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113843631
    378 https://doi.org/10.1186/s13073-019-0636-8
    379 rdf:type schema:CreativeWork
    380 sg:pub.10.1186/s40425-019-0575-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113479463
    381 https://doi.org/10.1186/s40425-019-0575-3
    382 rdf:type schema:CreativeWork
    383 grid-institutes:grid.18886.3f schema:alternateName Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK
    384 Tumour Profiling Unit, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK
    385 schema:name Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK
    386 Tumour Profiling Unit, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK
    387 rdf:type schema:Organization
    388 grid-institutes:grid.419765.8 schema:alternateName Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland
    389 Vital IT, Swiss Institute of Bioinformatics, 1015, Lausanne, Switzerland
    390 schema:name Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland
    391 Swiss Institute of Bioinformatics (SIB), 1015, Lausanne, Switzerland
    392 Vital IT, Swiss Institute of Bioinformatics, 1015, Lausanne, Switzerland
    393 rdf:type schema:Organization
    394 grid-institutes:grid.424926.f schema:alternateName GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    395 schema:name GI Cancer Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
    396 Translational Oncogenomics Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, SW3 6JB, London, UK
    397 rdf:type schema:Organization
    398 grid-institutes:grid.9851.5 schema:alternateName Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland
    399 schema:name Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, 1005, Lausanne, Switzerland
    400 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...